Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentations at November Conferences

SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today...
October 25, 2019 08:30 ET | Source: Zai Lab Limited

Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

SHANGHAI, China and SAN FRANCISCO, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
October 24, 2019 08:30 ET | Source: Zai Lab Limited

Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD)Zejula is now the only, once-daily PARP inhibitor approved...
October 04, 2019 07:30 ET | Source: Zai Lab Limited

Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
September 29, 2019 14:15 ET | Source: Zai Lab Limited

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

The PRIMA study, presented in a Presidential Symposium at the 2019 European Society for Medical Oncology congress and simultaneously published in The New England Journal of Medicine, demonstrates that...
September 03, 2019 07:32 ET | Source: Zai Lab Limited

Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019

-- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-- SHANGHAI, China and SAN FRANCISCO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ:...
August 27, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients

Study demonstrated comparable profile to non-Chinese patientsClinical study published in The Oncologist SHANGHAI, China, and SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited...
August 26, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentations at September Conferences

SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage biopharmaceutical...
August 20, 2019 07:30 ET | Source: Zai Lab Limited

Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019

SHANGHAI, China and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
August 12, 2019 07:30 ET | Source: Zai Lab Limited

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure...